{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:43:58Z","timestamp":1791575038821,"version":"4.3.4"},"reference-count":98,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.semnephrol.2019.12.006","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T18:59:50Z","timestamp":1582570790000},"page":"49-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma"],"prefix":"10.1016","volume":"40","author":[{"given":"Edgar A.","family":"Jaimes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2019.12.006_bib0001","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0003","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10456-004-2699-3","article-title":"Angiogenic growth factors and hypertension","volume":"7","author":"Sane","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0004","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.2007.11.5113","article-title":"Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?","volume":"25","author":"van Heeckeren","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0005","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0006","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0007","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1200\/JCO.2006.07.2066","article-title":"Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors","volume":"25","author":"Drevs","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0008","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/HYPERTENSIONAHA.117.09275","article-title":"Hypertension and VEGF (vascular endothelial growth factor) receptor tyrosine kinase inhibition: effects on renal function","volume":"70","author":"Boursiquot","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0009","first-page":"H1054","article-title":"VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells","volume":"274","author":"Hood","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0010","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/01.ATV.17.11.2793","article-title":"Vascular endothelial growth factor\/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium","volume":"17","author":"Horowitz","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0011","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/00005344-199606000-00011","article-title":"Effects of vascular endothelial growth factor on hemodynamics and cardiac performance","volume":"27","author":"Yang","year":"1996","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0012","doi-asserted-by":"crossref","first-page":"9904","DOI":"10.1074\/jbc.M412017200","article-title":"Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer","volume":"280","author":"Neagoe","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0013","first-page":"353","article-title":"Amniotic fluid\u2013soluble vascular endothelial growth factor receptor-1 in preeclampsia","volume":"95","author":"Vuorela","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0014","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/ajh.2012.97","article-title":"Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1","volume":"25","author":"de Jesus-Gonzalez","year":"2012","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0015","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1161\/HYPERTENSIONAHA.110.160481","article-title":"Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors","volume":"56","author":"Robinson","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0016","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1097\/00004872-200312000-00018","article-title":"Capillary rarefaction and abnormal cardiovascular reactivity in hypertension","volume":"21","author":"Ciuffetti","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0017","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0018","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0019","first-page":"658","article-title":"Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors","volume":"9","author":"Choueiri","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0020","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3","volume":"14","author":"Hu-Lowe","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0021","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/clpt.2014.63","article-title":"Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies","volume":"96","author":"Karovic","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0022","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0023","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0024","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0025","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0026","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","article-title":"Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100","volume":"26","author":"Schneider","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0027","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0028","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/01.HYP.35.2.539","article-title":"Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification","volume":"35","author":"Ogden","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0029","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","article-title":"Prognostic importance of comorbidity in a hospital-based cancer registry","volume":"291","author":"Piccirillo","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0030","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0031","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc072330","article-title":"Home blood-pressure monitoring in patients receiving sunitinib","volume":"358","author":"Azizi","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0032","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMc052954","article-title":"Reversible posterior leukoencephalopathy syndrome and bevacizumab","volume":"354","author":"Glusker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0033","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMc052954","article-title":"Reversible posterior leukoencephalopathy syndrome and bevacizumab","volume":"354","author":"Ozcan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0034","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0035","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0036","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0037","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","article-title":"Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension","volume":"50","author":"Izzedine","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0038","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0039","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0040","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0041","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0042","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0043","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","article-title":"Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study","volume":"8","author":"Rixe","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0044","doi-asserted-by":"crossref","first-page":"14448","DOI":"10.1073\/pnas.0703577104","article-title":"Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions","volume":"104","author":"Advani","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0045","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1152\/japplphysiol.00599.2003","article-title":"Effect of nitric oxide on exercise-induced proteinuria in rats","volume":"95","author":"Gunduz","year":"2003","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0046","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0047","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0048","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","article-title":"The role of vascular endothelial growth factor (VEGF) in renal pathophysiology","volume":"65","author":"Schrijvers","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0049","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature","volume":"290","author":"Kamba","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0050","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1097\/01.ASN.0000141038.28733.F2","article-title":"Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis","volume":"15","author":"Shimizu","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0051","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0052","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/jmcc.1999.1053","article-title":"Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis","volume":"32","author":"Katoh","year":"2000","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0053","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/00005344-200006000-00016","article-title":"Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts","volume":"35","author":"Katoh","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0054","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.kint.2018.12.025","article-title":"Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"95","author":"Cheung","year":"2019","journal-title":"Kidney Int"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2019.12.006_bib0055","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0056","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0057","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/jnci\/djt184","article-title":"MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells","volume":"105","author":"Leone","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0058","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri1936","article-title":"Cancer despite immunosurveillance: immunoselection and immunosubversion","volume":"6","author":"Zitvogel","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0059","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0060","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41581-018-0035-1","article-title":"Cardiorenal complications of immune checkpoint inhibitors","volume":"14","author":"Sury","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0061","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0062","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2215\/CJN.02340219","article-title":"AKI in patients receiving immune checkpoint inhibitors","volume":"14","author":"Perazella","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0063","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0064","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"12","author":"Abdel-Rahman","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/1753465816636557","article-title":"Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"10","author":"Abdel-Rahman","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0066","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0067","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1084\/jem.183.6.2533","article-title":"CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells","volume":"183","author":"Krummel","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0068","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0069","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0070","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0071","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0072","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0073","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0074","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0075","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0076","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0077","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/cc11454","article-title":"Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1)","volume":"17","author":"Kellum","year":"2013","journal-title":"Crit Care"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0078","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.ajkd.2019.03.433","article-title":"Kidney complications of immune checkpoint inhibitors: a review","volume":"74","author":"Shingarev","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0079","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0080","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11523-016-0426-9","article-title":"Severe hyponatremia and immune nephritis following an initial infusion of nivolumab","volume":"11","author":"Vandiver","year":"2016","journal-title":"Target Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0081","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0082","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","article-title":"Kidney injuries related to ipilimumab","volume":"32","author":"Izzedine","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0083","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ckj\/sfw024","article-title":"Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0084","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic syndrome with cancer immunotherapies: a report of 2 cases","volume":"70","author":"Kitchlu","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0085","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","article-title":"Ipilimumab-associated minimal-change disease","volume":"89","author":"Kidd","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0086","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/CJI.0000000000000189","article-title":"Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: a case report","volume":"40","author":"Daanen","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0087","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lungcan.2018.05.015","article-title":"Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: an autopsy case report","volume":"122","author":"Takahashi","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0088","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","article-title":"Nivolumab-associated acute glomerulonephritis: a case report and literature review","volume":"17","author":"Jung","year":"2016","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0089","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0090","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0091","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0092","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0093","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/CMR.0b013e32835fb524","article-title":"Ipilimumab-induced acute severe colitis treated by infliximab","volume":"23","author":"Pages","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0094","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0095","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1158\/1078-0432.CCR-06-2798","article-title":"The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy","volume":"13","author":"Abraham","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0096","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ncponc1173","article-title":"Mechanisms of disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC","volume":"5","author":"Figlin","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0097","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semnephrol.2019.12.006_bib0098","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929519301160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929519301160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:33:57Z","timestamp":1759448037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929519301160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0270929519301160"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2019.12.006","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2019.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}